Lisinopril dihydrate: Benchmark Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a lysine-derived, dihydrate salt of lisinopril, offering high-affinity inhibition of angiotensin converting enzyme (ACE) with an IC50 of 4.7 nM at 25°C (Tieku & Hooper 1992, DOI). The compound is supplied by APExBIO (B3290) at ≥98% purity, with validated mass spectrometry and NMR profiles (product page). Mechanistically, it blocks ACE-catalyzed conversion of angiotensin I to angiotensin II, lowering plasma angiotensin II and aldosterone, and inducing vasodilation. Lisinopril dihydrate is extensively utilized in research on hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. Its solubility profile (≥2.46 mg/mL in water with gentle warming) and stability support integration into diverse experimental platforms.

Biological Rationale

Regulation of blood pressure and fluid balance in mammals is primarily mediated by the renin-angiotensin-aldosterone system (RAAS). Angiotensin converting enzyme (ACE; EC 3.4.15.1) catalyzes the conversion of angiotensin I (decapeptide) to angiotensin II (octapeptide), a potent vasoconstrictor and aldosterone secretagogue (Tieku & Hooper 1992). Inhibition of ACE leads to decreased levels of angiotensin II, reduced aldosterone, and compensatory increases in plasma renin activity. These biochemical changes underpin the therapeutic and experimental use of ACE inhibitors in hypertension, heart failure, and renal disease models (related article).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate is a synthetic lysine analog of MK 421, formulated as a dihydrate for enhanced handling and stability. It selectively and competitively inhibits ACE, binding the active site zinc ion via its carboxyl terminal group (DOI). This inhibition is characterized by an IC50 of 4.7 nM in standard porcine kidney ACE assays at 25°C, pH 7.4. Lisinopril does not significantly inhibit related zinc metallopeptidases such as aminopeptidase A (AP-A; EC 3.4.11.2), aminopeptidase N (AP-N; EC 3.4.11.7), or aminopeptidase W, conferring high target specificity. The net result is a reduction in angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload in vivo. Lisinopril dihydrate is not metabolized in the liver and is excreted unchanged via the kidneys (APExBIO).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC50 of 4.7 nM at 25°C, pH 7.4 (Tieku & Hooper 1992, DOI).
• Does not significantly inhibit AP-A, AP-N, or AP-W at concentrations up to 10 µM, confirming high selectivity (Tieku & Hooper 1992, DOI).
• Decreases plasma angiotensin II and aldosterone concentrations while raising plasma renin activity in animal models (Tieku & Hooper 1992, DOI).
• Exhibits water solubility ≥2.46 mg/mL at room temperature with gentle warming; insoluble in ethanol (APExBIO, product page).
• Lisinopril dihydrate is supplied at ≥98% purity, as confirmed by mass spectrometry and NMR (APExBIO, product page).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used as a research tool to interrogate the renin-angiotensin system, particularly in:

• Hypertension models: Dissects the impact of ACE inhibition on blood pressure regulation (see comparative workflows).
• Heart failure studies: Evaluates afterload reduction and neurohormonal modulation in cardiac dysfunction.
• Acute myocardial infarction models: Probes for infarct size modulation and post-injury remodeling.
• Diabetic nephropathy research: Tests for renoprotective effects via glomerular hemodynamics.

This article extends prior coverage by providing a structured, citation-rich synthesis of evidence and clarifies mechanistic boundaries compared to earlier overviews (see previous summary).

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase A, N, or W at pharmacologically relevant concentrations (Tieku & Hooper 1992).
• It is not suitable for models requiring rapid, short-acting ACE blockade; its half-life is long-acting.
• The compound is insoluble in ethanol and most organic solvents; water is required for dissolution.
• Solutions are not stable for long-term storage; fresh preparation is advised for each experiment (APExBIO).
• Lisinopril dihydrate is not a substrate for hepatic metabolism; thus, drug-drug interaction studies involving CYP enzymes are not applicable.

Workflow Integration & Parameters

Lisinopril dihydrate (B3290) is provided as a solid, with a molecular weight of 441.52 g/mol and formula C21H35N3O7. For solution preparation, dissolve in sterile water to a concentration ≥2.46 mg/mL using gentle warming (<37°C) and ultrasonic agitation. Avoid ethanol, DMSO, or other organic solvents. Store lyophilized powder desiccated at room temperature; avoid repeated freeze-thaw cycles. For in vivo studies, dose and vehicle selection should be informed by target species and protocol requirements.

Shipping is performed on blue ice for small molecules. Each batch is supported by quality control documentation, including mass spectrometry and NMR validation. For up-to-date handling and benchmarking, refer to the APExBIO product page and compare with best-practice protocols (e.g., ACE inhibitor workflows), which this article updates with additional clarity on selectivity and integration parameters.

Conclusion & Outlook

Lisinopril dihydrate is a benchmark, long-acting ACE inhibitor with validated selectivity, high purity, and robust solubility in water. Its mechanistic specificity and reproducible IC50 underpin its use as a gold-standard reagent in hypertension, heart failure, myocardial infarction, and nephropathy models. As new research probes deeper into the renin-angiotensin system and its crosstalk with other peptidase pathways, accurate use of selective inhibitors such as Lisinopril dihydrate remains essential for mechanistic dissection and translational relevance (Tieku & Hooper 1992, APExBIO).